Her-2/neu fusion proteins

Details Her-2/neu fusion proteins Her-2/neu fusion proteins

2007-06-12

2007-06-12

Helms, Larry R. (Department: 1643)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C424S193100, C424S185100, C514S002600, C530S402000, C530S403000

Reexamination Certificate

active

09632507

ABSTRACT:
The present invention is generally directed to Her-2
eu fusion proteins, nucleic acid molecules encoding Her-2
eu fusion proteins, viral vectors expressing Her-2
eu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the Her-2
eu fusion proteins and/or nucleic acid molecules encoding the Her-2
eu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the Her-2
eu protein, including for uses in the treatment of malignancies associated with the Her-2
eu oncogene.

REFERENCES:
patent: 4803072 (1989-02-01), Dalton et al.
patent: 5723130 (1998-03-01), Hancock et al.
patent: 5726023 (1998-03-01), Cheever et al.
patent: 5801005 (1998-09-01), Cheever et al.
patent: 5811098 (1998-09-01), Plowman et al.
patent: 5846538 (1998-12-01), Cheever et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 5876712 (1999-03-01), Cheever et al.
patent: 5962428 (1999-10-01), Carrano et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6080409 (2000-06-01), Laus et al.
patent: 6146632 (2000-11-01), Momin et al.
patent: 6270769 (2001-08-01), Raychaudhuri et al.
patent: 6287569 (2001-09-01), Kipps et al.
patent: 6333169 (2001-12-01), Hudziak et al.
patent: 6429199 (2002-08-01), Krieg et al.
patent: 6664370 (2003-12-01), Cheever et al.
patent: 6734172 (2004-05-01), Scholler et al.
patent: 6942862 (2005-09-01), Cheever et al.
patent: 6953573 (2005-10-01), Cheever et al.
patent: 7005498 (2006-02-01), Steinaa et al.
patent: 2002/0018766 (2002-02-01), Roberts et al.
patent: 2002/0155527 (2002-10-01), Stuart et al.
patent: 0474727 (1997-07-01), None
patent: 0444181 (2001-10-01), None
patent: WO 90/14357 (1990-11-01), None
patent: WO91/02062 (1991-02-01), None
patent: WO 91/02062 (1991-02-01), None
patent: WO91/18926 (1991-12-01), None
patent: WO95/17210 (1995-06-01), None
patent: WO96/02555 (1996-02-01), None
patent: WO 96/18409 (1996-06-01), None
patent: WO 96/30514 (1996-10-01), None
patent: WO98/25574 (1998-06-01), None
patent: WO 99/46988 (1999-09-01), None
patent: WO99/57981 (1999-11-01), None
patent: WO00/04927 (2000-02-01), None
patent: WO00/20027 (2000-04-01), None
patent: WO00/29582 (2000-05-01), None
patent: WO00/44899 (2000-08-01), None
patent: WO 00/44899 (2000-08-01), None
patent: WO 01/74855 (2001-10-01), None
Bowie et al. Science, 1990, vol. 247, pp. 1306-1310.
Burgess et al., J of Cell Bio. vol. 111, pp. 2129-2138, 1990.
Lazar et al., Molecular and Cellular Biology, 1988, vol. 8, pp. 1247-1252.
Bork, Genome Research, 2000, vol. 10, pp. 398-400.
Osband and Ross, IMMUNOTHERAPY, pp. 193-195, 1990.
Dermer BIO/TECHNOLOGY, vol. 12, p. 320, Mar. 1994.
Ezzell, J. NIH Res. 1995 vol. 7 pp. 46-49.
Spitler, Cancer Biotherapy, 1995, vol. 10, pp. 1-3.
Chamberlain, R.S. et al. Expert Opinion on Pharmacotherapy, 1(4): 603-614, 2000.
Bernhard, H. et al., Endocrine-Related Cancer 9: 33-44, 2002.
Padhy, L. C. et al. Cell, 28: 866-871, 1982.
Venanzi, F.M. et al., Journal of the National Cancer Institute, 94(23): 1808-1809, 2002.
Schechter, A.L. et al. Nature, 312, 513-516, 1984.
Cornelia I. Bargmann et al., “TheNeuOncogene Encodes an Epidermal Growth Factor Receptor-Related Protein,” Jan. 1986, Nature, vol. 319, pp. 226-230.
Yasuhiro Nagata et al., “Peptides Derived From a Wild-Type Murine Proto-Oncogene c-erbB-2/HER2
euCan Induce CTL and Tumor Suppression in Syngeneic Hosts,” 1997, The American Association of Immunologists, The Journal of Immunology 159: 1336-1343.
Disis, et al., “Peptide-Based, but Not Whole Protein, Vaccines Elicit Immunity to HER-2
eu, an Oncogenic Self-Protein”;The American Association of Immunologistspp. 3151-3158 (1996).
Disis et al., “Peptide-Based, but Not Whole Protein, Vaccines Elicit Immunity to HER-2
eu, an Oncogenic Self-Protein”,The Journal of Immunology:3151-3158 (1996).
Dermer, Another Anniversary for the War on Cancer, Bio/Technology 12:320 (1994).
Disis and Cheever, Advances in Cancer Research 71:343-371 (1997).
Disis et al., Immunization with Homologous Foreign Proteins Generates Immunity Against “Self” Tumor Antigens, The FASEB Journal 10(6):A1470 (1996) ABSTRACT from Meetings, New Orleans, LA Jun. 2-6, 1996.
Ezzel et al., Cancer “Vaccines”: An Idea Whose Time Has Come?, J. NIH research 7:46-49 (1995).
Osband and Ross, Problems in the investigational study and clinical use of cancer immunotherapy, Immunology Today 11(6):193-195 (1990).
Spitler, Cancer Vaccines: The Interferon Analogy, Cancer Biotherapy 10(1):1-3 (1995).

Affiliated with

Also associated with

Rating

Her-2/neu fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Her-2/neu fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Her-2/neu fusion proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3888412